Today: 12 June 2026
AST SpaceMobile stock flirts with $100 as Zacks’ “Bear of the Day” clashes with satellite bulls
15 January 2026
2 mins read

AST SpaceMobile stock flirts with $100 as Zacks’ “Bear of the Day” clashes with satellite bulls

New York, Jan 15, 2026, 11:56 EST

  • AST SpaceMobile shares climbed roughly 4% amid mixed investor sentiment on the satellite-to-phone venture.
  • Zacks pointed to falling earnings forecasts and a high valuation; yet another Zacks comparison still ranked ASTS ahead of Verizon.
  • Commentators highlighted a 2026 launch target and carrier partnerships, yet cautioned that profits could remain elusive for years.

Shares of AST SpaceMobile climbed roughly 4% Thursday, hovering near $99 amid sharply divided opinions on the satellite-to-smartphone firm’s valuation and execution risks.

The tug-of-war is crucial now as “direct-to-device” connectivity—satellites linking regular smartphones without cell towers—shifts from demos to early commercial rollout. This shift has pushed what was once a niche telecom gamble into the spotlight for retail investors and telecom executives alike.

AST plans to roll out 45 to 60 satellites in 2026, a milestone its supporters believe could transform coverage in rural and remote regions. Skeptics, however, warn this ambitious timeline intensifies pressure on funding, production, and regulatory approvals, leaving scant margin for setbacks.

A Zacks “Bear of the Day” alert this week highlighted cuts in earnings per share (EPS) following a reported third-quarter shortfall, calling the stock’s recent surge overvalued. The note described the shares as trading at a “stratospheric” price-to-sales ratio—market value divided by projected revenue—and suggested some investors might prefer to take profits instead of chasing the rally. Sharewise

A separate Zacks report offered a more optimistic take, noting AST’s recent launch of the BlueBird 6 satellite, which it described as a record-setting commercial communications array in low Earth orbit. The analysis also emphasized AST’s spectrum acquisitions—including S-band and L-band rights—that might reduce the company’s dependence on carrier partners down the line.

The Zacks comparison also put Verizon under the microscope, highlighting its much bigger size and more stable footing in the U.S. telecom space, where growth is limited by a saturated wireless market. It flagged Verizon’s hefty debt and fierce rivalry with AT&T and T-Mobile, even as the company pushes into areas like vehicle-to-everything (V2X) communications — technology enabling cars to exchange data with other vehicles and road infrastructure — plus industrial 5G initiatives.

Motley Fool’s take tilted bullish, highlighting that AST’s network doesn’t need special phones and already counts more than 50 mobile service providers and telecom tech companies as partners—AT&T, American Tower, and Alphabet included. It pointed to third-party research predicting robust growth in space-based mobile broadband and noted analysts foresee a sharp revenue surge in the coming years.

Even the bull case carries warnings. Motley Fool highlighted that analysts don’t foresee profits until 2028 and flagged a consensus price target sitting below the stock’s recent trading price. It’s a clear sign some remain skeptical about backing the current valuation.

The risk is straightforward and harsh: delays in launch timing, rising satellite and component costs, or a need for more capital on less favorable terms could quickly squeeze the stock’s multiple. Zacks highlighted concerns over materials pricing and geopolitical factors, cautioning that large revenue contracts will likely be necessary to support the current share price.

ASTS is currently caught in a tricky spot—part telecom, part space hardware, part spectrum play. The coming quarters will likely depend more on launch schedules, coverage results, and new commercial contracts than on broad market predictions.

Stock Market Today

  • IperionX (ASX:IPX) Shares Face Revaluation Amid High P/B Ratio And Strong Long-Term Gains
    June 12, 2026, 12:46 AM EDT. IperionX (ASX:IPX) shares dropped 12% in the past month despite a 23% total return over the last year, reflecting cooled momentum after strong long-term gains. The stock trades at a premium price-to-book (P/B) ratio of 11x versus the Australian metals and mining industry average of 1.7x, indicating investor optimism on future revenue growth of 61.7% annually and earnings growth of 82.6%. However, with net losses of A$53.88 million and revenues under US$1 million, the elevated valuation prices in significant progress expectations on its titanium and rare earth projects. Risks such as project delays, funding setbacks, and slower commercialization could pressure the stock. The high P/B multiple suggests limited tolerance for underperformance compared to typical peers in the sector.

Latest articles

AI Names Drop, Oil Upends Inflation Bets, US Stocks Slip

Dow up 930 points after hours as tech lifts Nasdaq

12 June 2026
Dow soars 929.97 points for its strongest session in months as easing geopolitical risk and a rebound in tech drive ETFs higher after hours; chip stocks surge with the PHLX Semiconductor Index up 7.9%, while Adobe drops 5.44% after CFO exit despite raised forecasts.
Keel Infrastructure (KEEL) shares surge after $458 million AI data center deal closes

Keel Infrastructure (KEEL) shares surge after $458 million AI data center deal closes

12 June 2026
Keel Infrastructure Corp. surged 5.14% to $5.52 after closing $458 million in 1.250% convertible senior notes due 2032, with proceeds aimed at accelerating AI and high-performance computing data center projects; the notes’ initial conversion price is $7.41, about 25% above the June 4 close, while analysts’ 12-month price targets range from $3.00 to $8.00, averaging $5.52.
POET Technologies stock climbs before the bell as call-option volume spikes
Previous Story

POET Technologies stock climbs before the bell as call-option volume spikes

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead
Next Story

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

Go toTop